OncLive TV

Christine Chung, MD, contextualizes efficacy data with ficerafusp alfa plus pembrolizumab within the larger treatment paradigm for HPV-negative HNSCC.

Amitkumar Mehta, MD, details the FDA approval of tafasitamab with rituximab and lenalidomide for relapsed/refractory follicular lymphoma.

Massimo Cristofanilli, MD, discusses the next steps with camizestrant in ESR1-mutated HR-positive, HER2-negative advanced breast cancer.

C. Ola Landgren, MD, PhD, discussed the benefit of Dara-KRd in patients with multiple myeloma stratified by transplant eligibility, risk, and age.

Rami Komrokji, MD, shares results from a pooled analysis of outcomes with imetelstat based on prior therapy in transfusion-dependent lower-risk MDS.

Kate Gasparini, PharmD, BCOP, BCPPS, discusses issues with administering oral agents in pediatric patients with cancer or patients with dysphagia.

Yi Lin, MD, PhD, discusses the rationale for evaluating the onset of delayed toxicities following cilta-cel infusion in patients with multiple myeloma.

Jessica Paulus, ScD, discusses findings from a real-world, retrospective analysis of factors contributing to early-onset CRC.

Linda R. Duska, MD, MPH, discusses the need for continued research with concurrent chemoradiation in high-risk advanced cervical cancer.

Alan Tan, MD, emphasizes the importance of considering safety profiles and patient-related factors before selecting an IO regimen in metastatic ccRCC.

Jason S. Starr, DO, discusses DLL3 as a treatment target in extrapulmonary neuroendocrine carcinomas.

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Tahla Munir, MBChB, PhD, details the efficacy of first-line zanubrutinib and clinical implications for treatment selection in CLL.

Rana R. McKay, MD, FASCO, discusses data the combination of olaparib plus radium-223 vs radium-223 monotherapy in castration-resistant prostate cancer.

Amrita Krishnan, MD, discusses the potential clinical impact of trispecific antibodies in the management of relapsed/refractory multiple myeloma.

Lydia Scarfò, MD, discusses long-term data with BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.

David Curtis, MBBS, PhD, FRACP, FRCPA, discusses the use of post-transplant cyclophosphamide GVHD prophylaxis in matched donor peripheral blood SCT.

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, discusses safety and efficacy findings with JNJ-90014496 in relapsed/refractory large B-cell lymphoma.

Jyoti Mayadev, MD, discusses the prognostic and predictive significance of ctDNA in locally advanced cervical cancer.

Elena Elimova, MD, discusses the efficacy of zanidatamab with chemotherapy in HER2-positive advanced gastroesophageal adenocarcinoma.

Alexander Chehrazi-Raffle, MD, details safety data and the clinical implications of an analysis of second-line tivozanib for patients with metastatic RCC.

Amir Fathi, MD, discusses findings with ziftomenib in patients with relapsed/refractory, NPM1-mutant acute myeloid leukemia as demonstrated in KOMET-001.

Johannes Schetelig, MD, discusses outcomes with haploidentical related vs mismatched unrelated donor transplantation in high-risk AML, ALL, and MDS.

Saurabh Dahiya, MD, FACP, discusses safety and efficacy data from a study of the CAR T-cell therapy KITE-363 in relapsed/refractory B-cell lymphoma.

Deena M. Atieh Graham, MD, discusses notable shifts within the ovarian cancer landscape leading to better patient outcomes.

Douglas R. Adkins, MD, discusses the FDA approval of pembrolizumab for neoadjuvant and adjuvant treatment in resectable, locally advanced head and neck squamous cell carcinoma.

Guru P. Sonpavde, MD, discusses nivolumab plus ipilimumab in treatment-naive unresectable or metastatic urothelial carcinoma.

Tomasz Jankowski, MD, PhD, discusses THIO sequenced with cemiplimab for the third-line treatment of patients with ICI-resistant advanced NSCLC.

David J. Benjamin, MD, expands on real-world studies to help contextualize clinical trial data and inform treatment decisions in urothelial cancer.